{"schema_version":"secwatch.filing_event.v1","accession":"0002007919-26-000007","form_type":"8-K","ticker":"INBX","cik":"0002007919","company_name":"Inhibrx Biosciences, Inc.","filed_at":"2026-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.978977+00:00","generated_at":"2026-05-15T09:43:25.858310+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Inhibrx reports FY2025 net loss $140.1M; cash $124.2M plus $75M debt draw","bullets":["Net loss FY2025: $140.1M ($9.04/share), vs FY2024 net income $1.7B from 101 Transaction gain.","Cash $124.2M at Dec 31, 2025; received $75M gross proceeds from Oxford Finance on Mar 18, 2026.","R&D expense $113M (down 44% YoY); G&A $23.3M (down 82% YoY) due to lower clinical costs and prior-year transaction expenses.","ozekibart BLA submission for chondrosarcoma expected early Q2 2026; PFS data for CRC expansion Q2 2026.","INBRX-106: interim ORR data from Phase 2/3 HNSCC trial expected Q2 2026; PFS data at ESMO Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0002007919-26-000007","json":"https://secwatch.observer/filing/0002007919-26-000007.json","markdown":"https://secwatch.observer/filing/0002007919-26-000007.md","text":"https://secwatch.observer/filing/0002007919-26-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2007919/000200791926000007/0002007919-26-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2007919/000200791926000007/inhibrx-20260319.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:43:25.858310+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cf3fca152223b5d14c34e9df9bf1a2c2eda135f7","claim":"Inhibrx Biosciences, Inc. reported the fourth quarter and fiscal year 2025 results: net income Net loss was $32.8 million during the fourth quarter of 2025, or $2.11 per share, basic and diluted; Net loss was $140.1.","evidence_excerpt":"Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2007919/000200791926000007/0002007919-26-000007-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year 2025"},{"label":"Net income","value":"Net loss was $32.8 million during the fourth quarter of 2025, or $2.11 per share, basic and diluted; Net loss was $140.1"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}